Gri bio, inc.GRI.US Overview
GRI Overall Performance
GRI AI Analysis & Strategy
GRI Recent Performance
-3.48%
Gri bio, inc.
0.81%
Avg of Sector
-1.14%
S&P500
GRI PowerScanner
GRI Key Information
GRI Valuation Metrics
GRI Earnings Table
GRI Profile
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.